2022 annual financial data
Spero Therapeutics, Inc. 2022 Operating margin
Spero Therapeutics, Inc. 2022 operating margin with verified reported values.
Direct answer
Operating margin was -86.86%.
Operating income was -42,197,000 USD and net income was -46,415,000 USD.
Operating cash flow was -7,731,000 USD.
Get free Spero Therapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 48,579,000 USD
- Operating income
- -42,197,000 USD
- Net income
- -46,415,000 USD
- Operating cash flow
- -7,731,000 USD